These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 551646)

  • 1. Interspecies differences in sensitivity to the neuroleptic drug penfluridol.
    Metys J; Dlabac A
    Act Nerv Super (Praha); 1977 Jul; 19 Suppl 2():337-8. PubMed ID: 551646
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings: Pharmacological properties of a new oral long-acting neuroleptic drug penfluridol.
    Metys J; Dlavac A; Kazdová E
    Act Nerv Super (Praha); 1975; 17(4):219-20. PubMed ID: 816167
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of penfluridol and other drugs on apomorphine-induced stereotyped behavior in monkeys.
    Shintomi K; Yamamura M
    Eur J Pharmacol; 1975 Apr; 31(2):273-80. PubMed ID: 1171014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penfluridol blockade of apomorphine: dependence of duration on species and endpoint.
    Weissman A
    Eur J Pharmacol; 1975; 33(2):267-75. PubMed ID: 1237408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of serotonin and dopamine receptors in the mechanism of action of haloperidol and pirenperone].
    Maĭmets MO; Vasar EE; Nurk AM; Allikmets LKh
    Farmakol Toksikol; 1985; 48(2):15-8. PubMed ID: 3996566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of penfluridol on circling behavior and striatal DOPAC and serum prolactin concentrations in the rat.
    Annunziato LA; Wuerthele SM; Moore KE
    Eur J Pharmacol; 1978 Aug; 50(3):187-92. PubMed ID: 567584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series.
    Janssen PA; Niemegeers CJ; Schellekens KH; Lenaerts FM; Wauquier A
    Arzneimittelforschung; 1975 Aug; 25(8):1287-94. PubMed ID: 1242360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral pharmacologic studies in the monkey with DD-3480.
    Shibuya T; Nishimori T; Matsuda H; Chen PC
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):251-4. PubMed ID: 6125481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cumulative effects of penfluridol, a long-acting neuroleptic drug, as assayed by its behavioral actions.
    Kuribara H; Tadokoro S
    Jpn J Pharmacol; 1976 Dec; 26(6):693-702. PubMed ID: 1021605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyskinesia induced by long-term treatment with antipsychotic drugs: involvement of pre- and postsynaptic dopaminergic mechanisms.
    Engel J; Liljequist S; Goldstein M
    Adv Biochem Psychopharmacol; 1980; 23():387-95. PubMed ID: 6104913
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased mesolimbic 3H-spiroperidol binding in 4 week old offspring of nursing rat mothers treated with penfluridol.
    Engel J; Lundborg P
    Eur J Pharmacol; 1979 Dec; 60(4):393-5. PubMed ID: 575097
    [No Abstract]   [Full Text] [Related]  

  • 12. Dopamine receptor function and spontaneous orofacial dyskinesia in rats during 6-month neuroleptic treatments.
    Waddington JL; Cross AJ; Gamble SJ; Bourne RC
    Adv Biochem Psychopharmacol; 1983; 37():299-308. PubMed ID: 6138952
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanism of antiemetic action of penfluridol in the dog.
    Lee HK; Chung PM; Wang SC
    Eur J Pharmacol; 1978 Dec; 53(1):29-38. PubMed ID: 738357
    [No Abstract]   [Full Text] [Related]  

  • 14. FCE 23884, substrate-dependent interaction with the dopaminergic system. I. Preclinical behavioral studies.
    Buonamici M; Mantegani S; Cervini MA; Maj R; Rossi AC; Caccia C; Carfagna N; Carminati P; Fariello RG
    J Pharmacol Exp Ther; 1991 Oct; 259(1):345-55. PubMed ID: 1681087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
    Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
    J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A behavioral study of the changes in the CNS of mice after subchronic treatment with the dopamine autoreceptor agonist 3-PPP.
    Hjorth S; Jackson D; Carlsson A; Lindberg P
    Psychopharmacol Bull; 1982 Oct; 18(4):149-52. PubMed ID: 7156279
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroleptic/dopamine receptors: elevation and reversal.
    List S; Seeman P
    Adv Biochem Psychopharmacol; 1980; 24():95-101. PubMed ID: 6105811
    [No Abstract]   [Full Text] [Related]  

  • 18. Penfluridol: once-a-week oral maintenance neuroleptic in the management of chronic schizophrenics.
    Kurland AA; Ota KY
    Psychopharmacol Bull; 1975 Jan; 11(1):12-4. PubMed ID: 1091943
    [No Abstract]   [Full Text] [Related]  

  • 19. Absolute configuration of potentially neuroleptic rigid spiro amines. A study on the topography of the neuroleptic receptor.
    Carnmalm B; Johansson L; Rämsby S; Stjernström NE; Wägner A
    Acta Pharm Suec; 1979; 16(4):239-46. PubMed ID: 44421
    [No Abstract]   [Full Text] [Related]  

  • 20. Various effects of d-amphetamine in rats with selective lesions of brain noradrenaline - containing neurons or treated with penfluridol.
    Quattrone A; Bendotti C; Recchia M; Samanin R
    Commun Psychopharmacol; 1977; 1(6):525-31. PubMed ID: 564765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.